The population that can benefit from a new targeted therapeutic monotherapy is going to be negligible. The name of the game is, and will be, combination therapy.
Scottsdale, AZ (PRWEB) February 9, 2011
MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report entitled “Thought Leader Insight & Analysis: Multiple Myeloma,” designed to provide critical strategic insight for pharma and biotech companies with a stake in the market for treatments in this disease area.
This new report captures the opinions of a panel of global experts who specialize in multiple myeloma. They provide insight into the practice-changing ramifications of the data presented at the recent American Society of Hematology conference.
“Multiple myeloma has been transformed into a chronic but still life threatening disease,” according to Jeffrey Berk, Ph.D., MedPredict’s president. “Initial response rates to standard of care are very high. Revlimid, Velcade and dexamethasone gives a 100% response rate, with the very good partial response rate being 75%. From a commercial standpoint, this means that the population that can benefit from a new targeted therapeutic monotherapy is going to be negligible. The name of the game is, and will be, combination therapy.”
With this as a backdrop, some of the topics the panel tackles in this report include:
- What are the key unmet needs in multiple myeloma?
- How do they differentiate carfilzomib from bortezomib? Pomalidomide from lenalidomide?
- How will safety, efficacy and economics of new combinations drive the choice of therapy?
- Where will other mechanisms fit – including IMiD, HDAC, CS-1, CD38, CD56, CD138, FGFR3, AKT, CD66b, IGF-1, IL6, RAF/MEK, antibody drug conjugates and vaccines?
- What is new in transplant? Use of anticoagulants? Risk stratification? Treatment of skeletal related events?
Companies discussed in this report include: Abbott, Aeterna Zentaris, Amgen, Bayer, BioTest, Bristol-Myers Squibb, Boehringer Ingelheim, Aris, Celgene, Centocor, Cephalon, Genentech, Genmab, Gentium, GlaxoSmithKline, ImmunoGen, Johnson & Johnson, Keryx, Merck, Millennium, Nereus, Novartis, Onyx, and Signal Genetics.
The full report may be purchased by contacting MedPredict.
MedPredict (http://www.medpredict.com) maintains a proprietary database of over 1,000 global physician thought leaders. Based on primary interviews with these thought leaders, MedPredict publishes periodic therapeutic area reports to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and presentations, as well as clinical, regulatory and marketing activity.
For more information contact: